What is Henry Schein's cumulative cost basis?

Henry Schein (HSIC) reported cumulative cost basis of $1.38B in Q4 2025.

What is the long-term trend for Henry Schein's cumulative cost basis?

Over 3 years (2022 to 2025), Henry Schein's cumulative cost basis has grown at a 13.0% compound annual growth rate (CAGR), from $956M to $1.38B.

Henry Schein HSIC Cumulative Cost Basis

Cumulative Cost Basis at other companies

Globus MedicalGMED

——

West Pharmaceutical ServicesWST

——

Other financials

Income statement

See full

Revenue$3.4B+6.3%

Gross profit$1.1B+7.0%

Operating income$182.0M+4.0%

Net income$107.0M-2.7%

EPS (diluted)$0.92+4.5%

Balance sheet

See full

Cash & equivalents$138.0M+8.7%

Total debt$3.7B+17.2%

Total equity$3.3B-1.3%

Total assets$11.3B+7.9%

Cash flow

See full

Operating cash flow-$97.0M-362%

CapEx$25.0M-19.4%

Free cash flow-$122.0M-2,133%

Valuation

See full

Market cap$9.1B-0.6%

Enterprise value$12.69B+4.2%

P/E23.1×+0.5×

P/S0.7×0.0×

Profitability

See full

Gross margin31.2%-0.4pp

Operating margin4.9%-0.2pp

Net margin3%-0.3pp

FCF margin3.3%-1.0pp

Returns & leverage

See full

Return on equity12%+0.2pp

Debt / equity1.1×+0.2×

Current ratio1.4×0.0×

Where this comes from

Reported directly by Henry Schein in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Henry Schein’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Henry Schein's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Henry Schein's cumulative cost basis?: Henry Schein (HSIC) reported cumulative cost basis of $1.38B in Q4 2025.
What is the long-term trend for Henry Schein's cumulative cost basis?: Over 3 years (2022 to 2025), Henry Schein's cumulative cost basis has grown at a 13.0% compound annual growth rate (CAGR), from $956M to $1.38B.